CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF FACIAL SEBORRHEIC DERMATITIS WITH ORAL ITRACONAZOLE COMBINED WITH TOPICAL TACROLIMUS 0.03% AT DONG NAI DERMATOLOGY HOSPITAL IN 2025
Main Article Content
Abstract
Background: Facial seborrheic dermatitis is a common chronic and recurrent condition. The combination of oral itraconazole and topical tacrolimus 0.03% may provide good therapeutic efficacy; however, domestic data remain limited. Objectives: To describe the clinical features and evaluate the treatment outcomes of facial seborrheic dermatitis using a combination of oral itraconazole and topical tacrolimus 0.03% at Dong Nai Dermatology Hospital in 2025. Materials and methods: A cross-sectional descriptive study was conducted on 88 patients with facial seborrheic dermatitis at Dong Nai Dermatology Hospital in 2025. Results: The study included 88 patients, predominantly males, mainly aged 30–39 years. Lesions were mostly symmetrical with illdefined borders, commonly affecting the cheeks, eyebrows, and nasolabial folds. After treatment, the mean symptom scores decreased markedly. At baseline, 76.1% of patients had moderate disease and 21.6% had severe disease. After 4 weeks, the rate of good and complete improvement reached 97.8%. Gastrointestinal adverse effects associated with itraconazole were uncommon. After 2 weeks of treatment, topical tacrolimus may cause burning and stinging sensations; however, the stinging symptoms improved after 4 weeks. Conclusion: Seborrheic dermatitis of the face mainly occurs in young and middle-aged men, with onset after puberty, and a duration of illness usually less than 5 years. The lesions are characterized by symmetrical distribution. The combination of oral itraconazole and topical tacrolimus 0.03% provides a significant therapeutic effect. Symptom scores decrease rapidly from the second week and continue to improve after 4 weeks. The proportion of patients with moderate to severe cases achieves complete remission after treatment, with a high rate of good and complete remission. Adverse effects are rare, mostly mild and transient.
Keywords
Seborrheic dermatitis, itraconazole, tacrolimus
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Li J, Feng Y, Liu C, et al. Presence of Malassezia hyphae is correlated with pathogenesis of seborrheic dermatitis. Microbiology Spectrum. 2022. 10(1), e0116921, doi: 10.1128/spectrum.01169-21.
3. Dall’Oglio F, Nasca MR, Gerbino C, Micali G. An overview of the diagnosis and management of seborrheic dermatitis. Clinical, cosmetic and investigational dermatology. 2022. 15, 15371548, doi: 10.2147/CCID.S284671.
4. Bộ Y tế. Viêm da dầu. Hướng dẫn chẩn đoán và điều trị các bệnh da liễu. 2023. 228-232.
5. Lin Q, Panchamukhi A, Li P, et al. Malassezia and Staphylococcus dominate scalp microbiome for seborrheic dermatitis. Bioprocess and biosystems engineering. 2021. 44(5), 965-975, doi: 10.1007/s00449-020-02333-5.
6. Bubna AK. Topical Tacrolimus and Pimecrolimus in Dermatology: An Overview. Clinical Dermatology Review. 2024. 8(3), 185-196, doi: 10.4103/cdr.cdr_121_23.
7. Shemer A, Kaplan B, Nathansohn N, Grunwald MH, Amichai B, Trau H. Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open non-comparative study. The Israel Medical Association journal. 2008. 10(6), 417.
8. Trang NTT, Trâm PTB, Thảo PT, Vy TNK, Của TTH, Hùng TĐ. Nghiên cứu đặc điểm lâm sàng của bệnh nhân viêm da tiết bã điều trị phối hợp bằng itraconazol viên, kem terbinafin tại Bệnh viện Trường Y dược Cần Thơ. Tạp chí Y học Việt Nam. 2026. 559(1), doi: 10.51298/vmj.v559i1.17422.
9. An NT, Trung VT. Khảo sát nồng độ kẽm trong huyết thanh của bệnh nhân viêm da tiết bã. Tạp chí Y học Việt Nam. 2024. 542(1), doi: 10.51298/vmj.v542i1.10986.
10. Uyên ĐT, An TV, Vinh NM. Đánh giá kết quả điều trị bệnh viêm da tiết bã bằng itraconazole uống tại Bệnh viện Da liễu Thành phố Cần Thơ năm 2019-2021. Tạp chí Y Dược học Cần Thơ. 2021.38, 94-100.